# Glumetinib

Source: https://onco.cc/drugs/glumetinib/  
OnCo record `glumetinib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Glumetinib is a Chinese MET inhibitor approved in 2023 for lung cancers with MET exon 14 skipping, one of three such drugs approved in China and now in a phase 3 trial in gastric cancer.

## Summary

Haihe Biopharma's glumetinib (SCC244) was approved by the NMPA in 2023 for locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping, on the GLORY phase 2 trial. It joins savolitinib and vebreltinib as China's approved MET inhibitors, alongside capmatinib and tepotinib elsewhere. A phase 3 trial in MET-amplified gastric cancer with chemotherapy is registered.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Code: SCC244
- Modality: Oral selective MET tyrosine kinase inhibitor
- Mechanism: A highly selective type I MET kinase inhibitor for tumours driven by MET exon 14 skipping or amplification.
- Approvals: CN 2023: Locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping

## Sources

- ClinicalTrials.gov: trials of Glumetinib: https://clinicaltrials.gov/search?intr=SCC244

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [MET](https://onco.cc/targets/met/)
- trials: [A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in N](https://onco.cc/trials/nct06829459/), [Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer](https://onco.cc/trials/nct04270591/), [Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors](https://onco.cc/trials/nct06947291/)

---
JSON: https://onco.cc/api/v1/entities/glumetinib.json